Cerebrolysin is a peptide preparation derived through enzymatic breakdown of purified porcine brain proteins, resulting in a mixture of low-molecular-weight peptides and free amino acids. It has an approved pharmaceutical history in several countries (primarily in Europe, Asia, and Latin America) for neurological indications, making it one of the more clinically studied compounds in this library, though it is not FDA-approved in the United States.

Cerebrolysin is proposed to mimic the activity of endogenous neurotrophic factors, including brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), supporting neuronal survival, plasticity, and repair signaling. Because it’s a complex mixture rather than a single defined peptide, research has focused on its aggregate neurotrophic effects rather than a single isolated mechanism.

This is a summary, not an exhaustive review. Search the primary literature yourself: Cerebrolysin on PubMed →

The research-grade Cerebrolysin sold by Stack Science should be handled only by qualified personnel in a laboratory setting, stored and reconstituted per its Certificate of Analysis, and kept refrigerated once reconstituted. It is not FDA-approved and is not intended for human use in this form.